Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent before starting any study related procedures;~* Men 18 to 40 years of age;~* Men with mild to moderate vertex male pattern hair loss according to a modified Norwood/Hamilton classification scale (III vertex, IV or V);~* Participants willing to have a tattoo in the target area;~* Outpatients;~* Ability to comprehend the full nature and purpose of the study, including possible risks and side effects;~* Ability to co-operate with the Investigator and to comply with the requirements of the entire study.~Exclusion Criteria:~* Clinically relevant abnormal skin scalp findings which could interfere with the aim of the study; in particular, abrasion, actinic keratosis, inflammatory disorders or any other abnormality;~* Participants who had had hair transplant surgery or hair weaving;~* Clinically relevant abnormal laboratory values indicative of physical illness;~* Ascertained or presumptive hypersensitivity to the active principle and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study;~* History of local infections of skin and subcutaneous tissues of the head in the 3-months period before the trial inclusion;~* Relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases, that may interfere with the aim of the study;~* Suspicion of malignancy, including prostate cancer;~* History of infertility or difficulty fathering children;~* Participants who wish to conceive children during the study or whose sexual partner(s) is pregnant;~* Participants with active seborrheic dermatitis;~* History of varicocele;~* Concurrent use of systemic corticosteroids, topical corticosteroids in the balding area studied, anabolic steroids, or over-the-counter hair restorers;~* Use of the following drugs with antiandrogenic properties within 6 months of study entry: flutamide, cyproterone acetate, estrogen, progesterone, cimetidine, spironolactone or ketoconazole;~* Participants who had been treated with any of the following drugs within the past year: minoxidil (topical or oral), zidovudine, cyclosporine, diazoxide, phenytoin, systemic interferon, psoralens, streptomycin, penicillamine, benoxaprofen, tamoxifen, phenothiazines or cytotoxic agents;~* Use of finasteride or dutasteride within previous 12 months;~* Light or laser treatment of scalp within previous 3 months;~* Participation in the evaluation of any drug for 3 months before this study, calculated from the first day of the month following the last visit of the previous study;~* History of drug, alcohol \[\>2 drinks/day defined according to USDA Dietary Guidelines 2010\], caffeine (\>5 cups coffee/tea/day) or tobacco abuse (10 cigarettes/day).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- P-3074 + Finasteride Placebo (Type: EXPERIMENTAL): Participants received topical application of P-3074 contained finasteride 0.25% in morning onto dry scalp only (up to 4 puffs) and followed by placebo of finasteride 1 milligram (mg) tablet orally once daily for 24 weeks.
- P-3074 Vehicle + Finasteride Placebo (Type: PLACEBO_COMPARATOR): Participants received topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) and followed by placebo of finasteride 1 mg tablet orally once daily for 24 weeks.
- Oral Finasteride + P-3074 Vehicle (Type: ACTIVE_COMPARATOR): Participants received finasteride 1 mg tablet orally once daily followed by topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) for the 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).